Mona Ahmed Amin

Prof. Dr. Mona Ahmed Amin


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2003 in Chest
Verified
Journal Article
Closed access
PDF file
MAMona Ahmed Amin
Mona Ahmed Amin
AFAshraf Fawzy
Ashraf Fawzy
MHMagdy Abdel Hamid
Magdy Abdel Hamid
AEAbdou Elhendy
Abdou Elhendy

1 July 2013 in Clinical Transplantation
Verified
Journal Article
Open access
PDF file
MAMona Ahmed Amin
Mona Ahmed Amin
DSDina Sabry
Dina Sabry
LRLaila A. Rashed
Laila A. Rashed
WAWael M. Aref
Wael M. Aref
MEMohamed Ahmed El‐Ghobary
Mohamed Ahmed El‐Ghobary
YYYoussef Abdel‐Aziz Youssef
Youssef Abdel‐Aziz Youssef
Background Stem cell–based therapy has received attention as a possible alternative to organ transplantation. The aim of this study was to assess the safety and efficacy of autologous transplantation of bone marrow (BM)–derived stromal cells in post-HCV liver cirrhosis patients. Methodology 10 × 106 of isolated human bone marrow (HBM)-stromal cells in 10 mL normal saline were injected in the spleen of 20 patients with end-stage liver cirrhosis guided by the ultrasonography, and then patients were followed up on monthly basis for six months. Results A statistically significant decrease was detected in the total bilirubin, aspartate transaminase (AST), alanine transaminase (ALT) (p-value<0.01), prothrombin time (PT), and international normalized ratio (INR) levels (p-value<0.05), while a statistically significant increase in the albumin and PC (p-value<0.05) after follow-up. Conclusion This study suggested the safety, feasibility, and efficacy of the intrasplenic injection of autologous BM stromal cells in improving liver function in Egyptian patients with cirrhosis.

16 June 2020 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
MAMona Ahmed Amin
Mona Ahmed Amin
On 12 March 2020, the WHO declared that the coronavirus disease 2019 (COVID-19) constitutes a pandemic. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) have been reported among patients with COVID-19. However, it is currently uncertain whether the COVID-19 related liver damage/dysfunction is due mainly to the viral infection by itself or other coexisting conditions, such as the use of potentially hepatotoxic medications and the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ dysfunction. Individuals at high risk for severe COVID-19 are typical of older age and/or present with comorbid conditions such as diabetes, cardiovascular disease, and hypertension. This is also the same profile for those at increased risk for unrecognized underlying liver disease, especially nonalcoholic fatty liver disease. This could make them more susceptible to liver injury from the virus, medications used in supportive management, or hypoxia. So the aim of this review was to illustrate the clinical implications of COVID-19 on the liver in healthy and diseased states as well as the implications of common liver disorders on the outcome of COVID-19.

24 October 2005 in Chinese Journal of Digestive Diseases
Verified
Journal Article
Closed access
PDF file
MAMona Ahmed Amin
Mona Ahmed Amin
MHMagdy Abdel Hamid
Magdy Abdel Hamid
SSSleman Saba
Sleman Saba

1 June 2004 in Modern Rheumatology
Verified
Journal Article
Closed access
ASAmira A. Shahin
Amira A. Shahin
HSHesham A. Shahin
Hesham A. Shahin
MHMagdy A. Hamid
Magdy A. Hamid
MAMona Ahmed Amin
Mona Ahmed Amin
The aim of this study was to evaluate the incidence of morphologic and functional cardiac abnormalities in patients with systemic lupus erythematosus (SLE) and to correlate the findings with levels...

1 June 2020 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
PDF file
MAMona Ahmed Amin
Mona Ahmed Amin
ARAmal Radwan
Amal Radwan
AHAfaf Hemeda
Afaf Hemeda